Stuttgart - NASDAQ-listed Chart Industries, Inc. has sold its cryobiology business (MVE Biological Products) to Cryoport, Inc. for USD 320 million.
A CMS team led by Lead Partner Dr. Tobias Grau provided comprehensive legal advice to Chart on the transaction in Germany. The company already relied on the CMS team for the sale of its oxygen-related products business in Germany in 2018.
Chart Industries, Inc. is a leading independent global manufacturer of highly engineered equipment servicing multiple applications in the Energy and Industrial Gas markets. Being at the forefront of the clean energy transition, Chart has over 25 global locations worldwide from the United States to Asia, Australia, India, Europe and South America. The strategic decision to divest the cryobiological products business reflects Chart’s strategy and capital allocation approach to focus on its core capabilities and offerings while continuing to expand its presence in clean energy applications including LNG, hydrogen, biogas/biomethane, carbon capture and other renewable fueling sources.
Cryoport, Inc.is redefining temperature controlled supply chain support for the life sciences industry by providing a broad platform of temperature-controlled supply chain solutions, serving the Biopharma, Reproductive Medicine, and Animal Health markets. Cryoport serves clients in life sciences research, clinical trials, and product commercializations and supports life-saving advanced cell and gene therapies and delivers vaccines, protein producing materials, and IVF materials in over 100 countries around the world.
CMS Germany
Dr Tobias Grau, Lead Partner
Lena Stoll, Associate, both Corporate/M&A
Dr. Achim Lindemann, Partner
Dr Markus Meißner, Senior Associate, both Labor, Employment & Pensions
Dr Stefan Voß, Partner
Lukas Potstada, Senior Associate, both Real Estate & Public
Dr Rolf Hempel, Competition & EU
Dr Roland Wiring, Partner
Dr Eva Graske, Counsel, both Intellectual Property
Dr Martin Mohr, Counsel, Tax
Press Contact
presse@cms-hs.com
